2024/09/27 13:11:58 | |
---|---|
Price | |
4.295 CHF | |
Difference | 7.38% (0.30) |
ISIN | CH0256379097 |
Symbol | MOLN |
Exchange | SIX Swiss Exchange |
Currency | CHF |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 140 EUR |
Benchmark | SWISS MARKET INDEX |
Bid (Bid size) | 4.295 CHF (73) |
Ask (Ask size) | 4.33 CHF (20) |
Open | 4.03 CHF |
High | 4.36 CHF |
Low | 4.03 CHF |
Close (prev. day) | 4.00 CHF |
VWAP | 4.217885 CHF |
Volume (pcs) | 6,449 |
Trading volume | 27,201.14 |
Number of trades | 55 |
Last size | 21 |
Related Futures | - |
Related Options | - |
Date | Headline | Download | |
2024/09/11 | Global Equity Ratings | ||
2024/09/05 | Global Equity Ratings | ||
2024/08/12 | Global Equity Ratings | ||
2024/07/24 | Global Equity Ratings | ||
2024/07/12 | Global Equity Ratings |
2024/09/27 13:11:58 | |
---|---|
Price | |
4.295 CHF | |
Difference | 7.38% (0.30) |
ISIN | CH0256379097 |
Symbol | MOLN |
Exchange | SIX Swiss Exchange |
Currency | CHF |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 140 EUR |
Benchmark | SWISS MARKET INDEX |
Bid (Bid size) | 4.295 CHF (73) |
Ask (Ask size) | 4.33 CHF (20) |
Open | 4.03 CHF |
High | 4.36 CHF |
Low | 4.03 CHF |
Close (prev. day) | 4.00 CHF |
VWAP | 4.217885 CHF |
Volume (pcs) | 6,449 |
Trading volume | 27,201.14 |
Number of trades | 55 |
Last size | 21 |
6m | 1Y | 3Y | |
Perf (%) | +5.26% | +2.43% | -77.78% |
Perf (abs.) | +0.20 | +0.10 | -14.00 |
Beta | 0.60 | 0.35 | 0.37 |
Volatility | 79.83 | 69.98 | 73.33 |
Ø price 5 days | Ø volume 5 days (pcs.) | 4.038 CHF (13,650) |
Ø price 30 days | Ø volume 30 days (pcs.) | 4.823 CHF (14,603) |
Ø price 100 days | Ø volume 100 days (pcs.) | 5.104 CHF (51,456) |
Ø price 250 days | Ø volume 250 days (pcs.) | 4.282 CHF (30,276) |
YTD High | date | 9.500 CHF (2024/06/19) |
YTD Low | date | 3.105 CHF (2024/04/29) |
52 Weeks High | date | 9.500 CHF (2024/06/19) |
52 Weeks Low | date | 3.040 CHF (2023/10/27) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Stuttgart | 2019/06/28 | 15:43 | 12.90 EUR | 0.00 | 7 |
SIX Swiss Exchange | 2024/09/27 | 13:11 | 4.295 CHF | 0.03 | 55 |
London Stock Exchange | 2024/05/02 | 17:56 | 3.4068 CHF | 0.02 | 1 |
Frankfurt | 2019/06/28 | 08:03 | 12.88 EUR | 0.00 | 2 |
FINRA other OTC Issues | 2024/07/24 | 15:30 | 5.89 USD | 0.00 | 2 |
Berlin | 2019/06/28 | 15:59 | 12.90 EUR | 0.00 | 5 |
MOLECULAR PARTNERS AG |
- - |
Wagistrasse 14 - 8952 Schlieren |
Telefon: +41-44-755-77-00 |
Fax: +41-44-755-77-07 |
E-mail: info@molecularpartners.com |
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland. |
Patrick Amstutz | Chairman of Managing Board |
Michael Tobias Stumpp | Member of Executive Committee |
Alexander Zürcher | Member of Executive Committee |
Philippe Legenne | Member of Executive Committee |
Renate Gloggner | Member of Executive Committee |
Agnete Brunsvik Fredriksen | Member of the administrative board |
Dominik Höchli | Member of the administrative board |
Michael Vasconcelles | Member of the administrative board |
Steven Holtzman | Member of the administrative board |
Vito Palombella | Member of the administrative board |
Sandipkumar S. Kapadia | Member of the administrative board |
William Burns | Chairman of the administrative boar |
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer